News & Updates

Histologic variables of renal biopsy in lupus nephritis (LN) are significantly associated with kidney failure and mortality, suggests a recent study.

New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Use of selexipag shows promise in the treatment of systemic sclerosis (SSc) digital vasculopathy, according to a study.

Use of ixekizumab (IXE) for 3 years in patients with axial spondyloarthritis (axSpA) is safe, which is consistent with the previously established long-term safety profile, reports a study. Treatment with IXE results in sustained improvement of disease activity through 156 weeks.

In a pooled, post hoc analysis of the AURA-LV and AURORA 1 studies, lupus nephritis (LN) patients with moderate-to-high baseline levels of proteinuria (UPCR* ≥2 to ≥3 mg/mg) who were receiving add-on voclosporin achieved higher renal response rates and earlier UPCR reductions vs those who were only treated with the control regimen.